Kornimate/medical-research-clean huggingface dataset:
functional cure of hepatitis b in hiv/hbv co-infected patients

Conditions: AIDS; Hepatitis B

Summary: evaluate the potential of art combined with interferon therapy to achieve functional cure of hepatitis b in hiv/hbv co-infected patients

this is a prospective, non-randomized, clinical observational cohort study. the subjects are the advantageous population for functional cure of hepatitis b in hiv/hbv co-infected patients . depending on whether interferon therapy is used in the real world , the patients are divided into two groups: the art combined with interferon group and the art alone group, with 30 cases in each group. hepatitis b surface antigen seroclearance rate and seroconversion rate will be observed during the study period.

Eligibility criteria:
inclusion criteria: 1. age 18-65 years old, gender unrestricted. 2. meeting the people's republic of china health industry standard (ws293-2008) - "aids and hiv infection diagnostic criteria", confirmed as hiv-1 infected. 3. hbsag positive for more than 6 months. 4. at least 1 year of art treatment prior to screening, and currently undergoing art treatment with hbsag \ 200 cells/μl and hiv-rna\<20 copies/ml. exclusion criteria: 1. pregnant, nursing, planning pregnancy, or with severe mental disorders or uncontrolled epilepsy. 2. co-infected with hepatitis a, c, d, or e viruses. 3. with other chronic liver diseases like autoimmune hepatitis, drug-induced hepatitis, alcoholic hepatitis, genetic metabolic liver diseases, or moderate to severe fatty liver. 4. with autoimmune diseases like rheumatoid arthritis, psoriasis, or lupus. 5. post organ transplant, planning organ transplant, diagnosed or suspected of liver cancer or other malignant tumors, or undergoing immunosuppressive treatment. 6. with severe diseases of heart, lungs, kidneys, brain, retinal disorders, or uncontrolled hypertension or diabetes. 7. excessive alcohol (average daily alcohol intake \>40g for men, \>20g for women) or drug users. 8. participated in other interventional trials within the last three months, or other situations deemed inappropriate for inclusion by researchers.

Keywords: hiv/hbv co-infection functional cure interferon
compare the efficacy and safety of dabigatran and enoxaparin in patients with portal vein thrombosis with cirrhosis

Conditions: Portal Vein Thrombosis; Liver Cirrhosis

Summary: portal vein thrombosis (pvt) is prevalent among patients with cirrhosis, and its prevalence rises with the severity of liver disease. numerous studies have indicated that patients developing pvt experience elevated portal pressure and associated complications, such as increased incidence of variceal bleeding, higher rates of failed variceal bleed control, rebleeding, and short-term mortality. additionally, the development of pvt adversely affects post-transplant outcomes, correlating with increased 30-day mortality among transplant recipients with pvt. current guidelines lack clarity regarding the optimal choice of anticoagulation therapy for patients with cirrhosis. this study aims to evaluate the efficacy and safety of enoxaparin and dabigatran in achieving complete recanalization of portal vein thrombosis in cirrhotic patients over a 6-month period.

study population: cirrhosis with portal vein thrombosis within 6 months of diagnosis of portal vein thrombus study design - a prospective, randomized, single center open label study block randomization, block size - 10 study site - department of hepatology, ilbs, new delhi from the study will be conducted on the consecutive patients with liver cirrhosis with portal vein thrombosis. study period -1 year monitoring and assessment * at enrollment: 1. complete history and physical examination 2. etiology of cirrhosis 3. presenting symptoms 4. severity of ascites, jaundice 5. pattern and number of prior decompensation 6. ugie and variceal status 7. complete physical evaluation 8. hemogram, kidney function test, liver function test, inr 9. ultrasound abdomen with spleno-portal axis doppler / cect upper abdomen 10. fibroscan-liver and spleen 11. 2d-echo, ecg 12. afp at follow-up (1month, 3 month, 6 month, 9 month 12month) 1. complete history and physical examination 2. pattern and number of decompensation 3. meld, ctp, apri, albi score 4. hemogram, kidney function test, liver function test, inr 5. ultrasound abdomen with spleno-portal axis doppler / cect upper abdomen

Eligibility criteria:
inclusion criteria: 1. age \>18 years 2. cirrhosis with portal vein thrombosis within 6 months of diagnosis/symptomatic pvt/pvt in potential transplant recipient. exclusion criteria: 1. contraindications to anticoagulant therapy, such as active bleeding, recent major surgery, or known hypersensitivity to study medications. 2. ctp \>10 3. hepatocellular carcinoma 4. tumoral pvt 5. isolated gastric varices with red colour signs 6. peptic ulcer disease with large ulcers 7. pregnant or breastfeeding women 8. thrombocytopenia (platelet count \<50,000/μl) 9. patients with concurrent acute kidney injury or chronic kidney disease stage 4 or 5 10. those not giving consent for therapy
genetic markers in patients with colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: determination of genetic markers for colorectal cancer may improve the identification of patients who are at highest risk for relapse. purpose: this clinical trial is studying the importance of genetic markers for detecting relapse in patients with colorectal cancer.

objectives: * determine the clinical and pathologic significance of unstable dna elements in colorectal cancer (tumor microsatellite instability). * determine the clinical and pathologic significance of loss of heterozygosity for chromosomes 5, 8, 17, and 18 (as the primary targets) and of chromosomes 1, 14, and 22 (as the secondary targets) in colorectal cancer. outline: dna is examined for unstable elements (microsatellite instability and loss of heterozygosity) by analyzing at least 10 separate (ca)n-repeats localized to 5 separate chromosomes (5q, 8p, 15, 17p, and 18q). loss of heterozygosity is analyzed for at least four chromosomal arms (5q, 8p, 17p, and 18q) and later other chromosomes (e.g., 1, 14, and 22). immunohistochemistry is used to test for the presence or absence of the genes involved in dna mismatch repair (hmlh1 and hmsh2). patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment. projected accrual: this study will accrue up to 708 specimens.

Eligibility criteria:
disease characteristics: * must have had a resectable adenocarcinoma of the colon or rectum and must have participated in one of the following ncctg randomized clinical trials: * 784852: no treatment control versus levamisole versus levamisole plus fluorouracil (5-fu) * 794604: no treatment control versus 5-fu by portal vein infusion * 794751: postoperative radiation versus postoperative radiation plus sequential chemotherapy with methyl ccnu and 5-fu * 844652: an intergroup study - an evaluation of levamisole plus 5-fu as surgical adjuvant treatment for resectable adenocarcinoma of the colon * 864751: phase iii protocol for surgical adjuvant therapy of rectal carcinoma: a controller evaluation of (a) protracted-infusion 5-fu as a radiation enhancer and (b) 5-fu plus methyl-ccnu chemotherapy * 874651: m/n - a controller evaluation of recombinant interferon-gamma (ifl gm) and 5-fu and folinic acid with or without levamisole as adjuvant treatment for resectable adenocarcinoma of the colon * 894651: a controller phase iii evaluation of 5-fu combined with levamisole and leucovorin as adjuvant treatment for resectable colon cancer * tissue blocks from the primary colorectal cancer must have been received by the ncctg operations office

Keywords: colon cancer rectal cancer
study utilizing biozek covid-19 antigen rapid test

Conditions: Covid-19 Testing

Summary: this is a research study to evaluate the sensitivity and specificity of biozek covid-19 antigen rapid test (saliva) and biozek covid-19 antigen rapid test (nasopharyngeal swab) on samples that are self-collected; and to perform analysis to compare results. in addition, to obtain rt-pcr test results, performed prior to enrollment, and compare all three results.


Eligibility criteria:
inclusion criteria: * subjects must be ≥18 years of age and have had an rt-pcr test performed prior to enrollment. * subjects must be able to understand and willingly sign a written informed consent. additionally, participants need to meet at least 1 of the criteria listed below: * currently experiencing symptoms of covid-19. * be clinically diagnosed or suspected to have covid-19. * recent past (3 weeks) exhibited symptoms of covid-19. * be capable of performing a self-collection of a nasopharyngeal sample with use of nasal swab kit. * be capable of performing a self-collection of an oral fluid sample with use of oral fluid collection kit. * interacted with a covid-19 positive individual. exclusion criteria: subjects who meet any of the following exclusion criteria may not be enrolled in this study: * cannot perform self-collection of a nasopharyngeal sample with use of nasal swab kit. * cannot perform self-collection of an oral fluid sample with use of oral fluid collection kit. * have a deviated nasal septum. * cognitively impaired individuals resulting in the inability to provide informed consent

Keywords: covid-19 antigen rapid test
evaluate saxagliptin in adult indian patients with type 2 diabetes inadequate glycemic control

Conditions: Type 2 Diabetes

Summary: saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. this study is designed to evaluate the efficacy and safety in adult indian patients with inadequate glycaemic control with diet and exercise.


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes * patients should be drug naïve ie, not received medical treatment for diabetes * hba1c ≥ 7.2% and ≤10.0% (at enrolment), hba1c ≥ 7.0% and ≤10.0% (at randomization) exclusion criteria: * insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes) * type 1 diabetes,history of ketoacidosis or hyperosmolar non-ketonic koma

Keywords: dpp-4 inhibitors hba1c incretins
advanced multi-modal wearable sensing for the prediction of pre-term labor

Conditions: Pregnancy Preterm

Summary: percent agreement of vital signs monitoring between the experimental sensor and standard of care monitoring

the primary objective of the prentice study is to assess and validate emg performance of the new home-use sensor with extended battery life in detecting continuous ehg in a range of uterine contraction intensities, frequencies, and durations compared to gold-standard fda-cleared tocodynamometer (ge corometrics 250cx) in non-stress testing for antepartum surveillance. an "at-home" study will validate the developed modifications to the wearable sensors system that provides a continuous electrohysterography (ehg) along with other additional physiological parameters (e.g. heart rate, heart rate variability, sleep quality, physical activity, and continuous blood pressure) for longitudinal monitoring in the home setting.

Eligibility criteria:
* maternal age \>18 years old * pregnant mothers \>13 weeks (home study only) * pregnant mothers \>26 weeks undergoing nonstress testing or delivering * singleton pregnancy (inpatient or clinic visit patients only) * history of preterm labor or premature birth, active smoker, chronic condition (ex: htn or dm), or an interval of less than 6 months between the prior pregnancy * singleton pregnancy (home study only) * no fetal abnormality or chromosomal abnormality * subjects willing and able to comply with requirements of the protocol exclusion criteria * women who refuse to signed the informed consent form * maternal age under 18 years old * multiple pregnancy * known major fetal malformation or chromosomal abnormality * medical or obstetric problem that would preclude the use of abdominal electrodes * inability to consent to this study due to medical illness, diminished intellectual capacity, or language barrier * women using pacemakers
dietary plant hormone and mental health

Conditions: Dietary Behavior; Stress; Sleep; Depression, Anxiety

Summary: the aim of this cross-sectional online study is to investigate the association between regular feeding behavior and stress, sleep as well as anxiety and depressive symptoms in healthy subjects.

the gut-microbiota-brain (gmb) axis has a multidirectional communication between the intestine, the microbiota, and the central nervous system (cns). over the past decade, there has been extensive research showing that the gmb axis has a profound influence not only on neurological disorders but also on neural development, activation of the neuroendocrine axis and neurotransmission, as well as modulation of complex human behaviors. thus, the gbm-axis is involved in the regulation of stress, emotions, behaviour, and higher cognitive functions. as the gmb plays an essential role in human psychological functioning and mental health, the dietary manipulation of the microbiome may have direct effects on mental well-being, sleep, anxiety and depressive symptoms.

Eligibility criteria:
inclusion criteria: * age 18 to 30 exclusion criteria: * none
quantifying myofascial dysfunction in post-stroke pain

Conditions: Myofascial Dysfunction

Summary: the purpose of this study is to quantify the extent of glycosaminoglycan/hyaluronic acid (gag/ha) accumulation using t1rho (t1ρ) mri in the paretic versus non-paretic shoulder rotator muscles, and correlate the t1ρ magnetic resonance imaging (mri) measurements with us echo texture measurements to develop a clinic-friendly tool to infer the extent of ha accumulation; and to distinguish between latent versus active post stroke shoulder pain (pssp) using ultrasound (us) shear strain mapping of the same muscles on the paretic side compared with the non-paretic side.

shoulder pain is extremely common after stroke and occurs in 30-70% of patients. chronic post stroke shoulder pain (pssp) contributes to depression, interferes with motor recovery, and decreases quality of life. although pssp is thought to be caused by damage to the myofascial tissues around the shoulder joint, the pathophysiology of myofascial dysfunction and pain in pssp has not been elucidated, leading to missed opportunities for early diagnosis, and variable success with pain management. the accumulation of ha in muscle and its fascia can cause myofascial dysfunction. ha is a gag and a chief constituent of the extracellular matrix of muscle. in physiologic quantities, it functions as a lubricant and a viscoelastic shock absorber, enabling force transmission during muscle contraction and stretch. reduced joint mobility and spasticity can result in focal accumulation and alteration of ha in muscle, leading to the development of taut bands, dysfunctional gliding of deep fascia and muscle layers, reduced range of motion (rom), and pain. muscle ha concentrations can be imaged using t1ρ mri, and myofascial dysfunction can be assessed using echo texture analysis and shear strain mapping on quantitative us, which may serve as useful biomarkers to elucidate the pathophysiology of myofascial dysfunction in pssp.

Eligibility criteria:
inclusion criteria: * 18 years or older * hemiparesis from ischemic or hemorrhagic stroke * 4-120 months post-stroke with hemiparesis since the incidence and intensity of pssp * show a difference of more than 10 degrees of passive er-rom between non-paretic and paretic shoulders with or without pain * able to provide informed consent and comply with testing protocols exclusion criteria: * received treatment for spasticity with botulinum toxin or intrathecal baclofen within the past three months * have another neurologic condition that may affect motor response (e.g. parkinson's disease, amyotrophic lateral sclerosis (als), multiple sclerosis (ms)) * have a contraindication to mri (claustrophobia, magnetic pacemakers and clips) * have non-musculoskeletal pssp such as only central pain or chronic regional pain syndrome (crps) * have a complicated medical condition, or significant injury to either upper limb.

Keywords: glycosaminoglycan hyaluronic acid post stroke shoulder pain
spinal muscular atrophy and cardiac autonomic function

Conditions: Spinal Muscular Atrophy

Summary: respiratory dysfunction is the major cause of morbidity and mortality in patients with spinal muscular atrophy (sma). air stacking is a clearance airway technique frequently used but its effects on cardiac autonomic function in patients with spinal muscle atrophy is not clear. objective: to evaluate the acute effect of air stacking and posture on cardiac autonomic function in patients with spinal muscular atrophy types ii and iii. methods: patients with spinal muscle atrophy type ii and iii will be recruited. electrocardiogram signals will be recorded for analyses of heart rate variability during air stacking in supine and sitting position.

background: respiratory dysfunction is the major cause of morbidity and mortality in patients with spinal muscular atrophy. air stacking is a clearance airway technique frequently used but its effects on cardiac autonomic function in patients with spinal muscle atrophy is not clear. objective: to evaluate the acute effect of air stacking and posture on cardiac autonomic function in patients with spinal muscular atrophy types ii and iii. methods: patients with spinal muscle atrophy type ii and iii will be recruited. electrocardiogram signals will be recorded for analyses of heart rate variability during air stacking in supine and sitting position. data will collected before, during and after air stacking and will be compared using anova repeated measures or kruskal-wallis anova on ranks, followed by tukey test. the relationship between heart rate variability indexes and age will be evaluated by pearson correlation. significant level will be set at 5%.

Eligibility criteria:
inclusion criteria: * diagnosis of sma types ii and iii, * absence of acute respiratory disease in the last two weeks, * agreement to participate in the study, * according written informed consent and * at least 5 years old. exclusion criteria: * respiratory disease in the last two weeks

Keywords: spinal muscular atrophy heart rate variability posture air stacking
comparison of blephex to miboflo as treatment options for blepharitis

Conditions: Meibomian Gland Dysfunction; Dry Eye; Posterior Blepharitis

Summary: the goal of this study is to compare which treatment - blephex or miboflo - will be a better option for patients suffering from dry eye secondary to meibomian gland dysfunction.

the investigators have previously studied the effect of the blephex instrument (debridement of lid debris) in relieving signs and symptoms of blepharitis (connor cg et al, arvo 2014). this previous study demonstrated positive results from the blephex treatment. warming the eyelids (e.g., using warm wash cloths) still remains a viable treatment option for this disease. however, patients are often non-compliant with warm compress therapy due to the requirement of performing it at least twice per day. the miboflo delivers uniform and consistent amounts of heat to the eyelid. it is suggested that two treatments over 30 days is adequate to relieve signs and symptoms of meibomian gland dysfunction. this equipment is currently used in optometric practices in this country. there are no clinical studies comparing blephex and miboflo as treatment options for blepharitis. hence, the current study will provide new and useful information on which treatment option may be better for treating blepharitis and meibomian gland dysfunction. part of this study will also investigate if a combination of blephex and miboflo treatments is more beneficial to the patient. the data generated will directly benefit clinical practice and impact several millions of patients who suffer from this blepharitis and / or meibomian gland dysfunction.

Eligibility criteria:
inclusion criteria: * must have dry eye secondary to meibomian gland dysfunction (posterior blepharitis) exclusion criteria: * must not have active ocular surface infections. must not be currently using steroids or immunosuppression eye drops.
comparative effectiveness study of two forms of ketamine for treatment-resistant depression

Conditions: Treatment Resistant Depression

Summary: the goal of this study is to compare the effectiveness of two formulations of ketamine - spravato® and racemic ketamine - in people with treatment-resistant depression (trd). the main questions it aims to answer are: * how the two formulations compare in terms of their effectiveness in treating trd. * how the two formulations compare in their acceptability to patients, safety, effects on patient quality of life and function, and cost effectiveness. participants will be randomised to receive either spravato® or racemic ketamine treatment and asked to complete some questionnaires to assess the effects on mood, treatment acceptability, side effects, quality of life and function, and health economic outcomes.

the trek study is a randomized, prospective, rater blinded (primary outcome raters), parallel group, comparative effectiveness trial of racemic ketamine and spravato®, comparing their effectiveness, acceptability, safety, effects on quality of life (qol), function and cost effectiveness after 4 weeks - 6 months of treatment in people with trd. participants will be recruited from clinics/hospitals that are providing racemic ketamine and spravato® treatment services for trd. participants will be referred, treated and followed up as per the clinic's normal clinical practice. participants who consent to participate in this research study will undergo other processes in addition to the standard treatment procedures provided by their clinic: * randomisation to receive racemic ketamine or spravato®. * completion of questionnaires to measure treatment effects on mood, acceptability, safety, quality of life and function and cost effectiveness.

Eligibility criteria:
inclusion criteria: * adult with treatment-resistant depression (trd: not responded adequately to at least two different antidepressants of adequate dose and duration) who has a current depressive episode (dsm 5) * assessed and attested by clinic psychiatrist as appropriate to receive either racemic ketamine or spravato® ketamine treatment for trd * aged ≥18 years * written informed consent for research study obtained exclusion criteria: * not able to give informed consent * any physical or mental condition which, in the opinion of the investigator, could interfere with study participation including outcome assessments * patients who require an interpreter/translator for the clinic consent process, due to the infeasibility of obtaining an interpreter for research assessments, including self-rated scales
the detection of circulating tumor cells (ctc) in patients with nsclc undergoing definitive radiotherapy or chemoradiotherapy

Conditions: Non-small Cell Lung Cancer

Summary: ctc levels collected pre-surgery will be correlated with pathological samples.

patients with nsclc who undergo radiation as part of a definitive course of treatment will be enrolled. blood collections will be obtained before, during, and after radiotherapy. we will collect demographic and treatment data and explore \& describe the pattern of ctc detection in all patients

Eligibility criteria:
inclusion criteria: * patients with biopsy-proven nsclc who are undergoing definitive radiotherapy as a part of their treatment regimen. * age 18 or older * signed informed consent * patients who are incapable of providing informed consent are excluded from participating in this study.